Journey Medical Corporation DERM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Journey Medical Corporation in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Journey Medical Corporation's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Journey Medical Corporation's additional paid-in capital?
- Journey Medical Corporation (DERM) reported additional paid-in capital of $131.52M in Q1 2026.
- How has Journey Medical Corporation's additional paid-in capital changed year-over-year?
- Journey Medical Corporation's additional paid-in capital increased by 16.8% year-over-year, from $112.64M to $131.52M.
- What is the long-term trend for Journey Medical Corporation's additional paid-in capital?
- Over 5 years (2020 to 2025), Journey Medical Corporation's additional paid-in capital has grown at a 90.7% compound annual growth rate (CAGR), from $5.17M to $130.31M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.